MX360638B - Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos. - Google Patents
Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.Info
- Publication number
- MX360638B MX360638B MX2013012579A MX2013012579A MX360638B MX 360638 B MX360638 B MX 360638B MX 2013012579 A MX2013012579 A MX 2013012579A MX 2013012579 A MX2013012579 A MX 2013012579A MX 360638 B MX360638 B MX 360638B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical agents
- lipophilic pharmaceutical
- preparing
- methods
- lipophilic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000008177 pharmaceutical agent Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003978 infusion fluid Substances 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480259P | 2011-04-28 | 2011-04-28 | |
| PCT/US2012/034361 WO2012148799A1 (en) | 2011-04-28 | 2012-04-20 | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013012579A MX2013012579A (es) | 2014-03-26 |
| MX360638B true MX360638B (es) | 2018-11-12 |
Family
ID=46045121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013012579A MX360638B (es) | 2011-04-28 | 2012-04-20 | Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos. |
| MX2018013788A MX380805B (es) | 2011-04-28 | 2012-04-20 | Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013788A MX380805B (es) | 2011-04-28 | 2012-04-20 | Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos. |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9364433B2 (enExample) |
| EP (2) | EP2701684B1 (enExample) |
| JP (2) | JP6080312B2 (enExample) |
| CN (2) | CN103635179B (enExample) |
| AR (1) | AR086115A1 (enExample) |
| AU (1) | AU2012250050B2 (enExample) |
| CA (1) | CA2834262C (enExample) |
| DK (2) | DK3238709T3 (enExample) |
| ES (2) | ES2822350T3 (enExample) |
| HU (2) | HUE051400T2 (enExample) |
| IL (1) | IL229067B (enExample) |
| MX (2) | MX360638B (enExample) |
| PL (2) | PL2701684T3 (enExample) |
| TW (1) | TWI626059B (enExample) |
| WO (1) | WO2012148799A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| AU2010302350B2 (en) | 2009-10-02 | 2015-06-18 | Journey Medical Corporation | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US12661407B2 (en) | 2010-04-08 | 2026-06-23 | Journey Medical Corporation | Compositions, gels and foams with rheology modulators and uses thereof |
| CN103402543B (zh) * | 2010-12-16 | 2015-09-16 | 德克萨斯州立大学董事会 | 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法 |
| AU2012250050B2 (en) * | 2011-04-28 | 2017-04-06 | Platform Brightworks Two, Ltd. | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
| US20140178479A1 (en) * | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| GR20120100242A (el) * | 2012-05-04 | 2014-01-02 | Micrel Ιατρικα Μηχανηματα Α.Ε., | Αντλια και προγεμισμενος ασκος/σετ αναλγησιας |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| JP6083770B2 (ja) * | 2013-09-13 | 2017-02-22 | 昭子 板井 | 水溶液製剤及びその製造方法 |
| WO2015126502A2 (en) | 2013-12-03 | 2015-08-27 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| US11696883B2 (en) | 2014-05-23 | 2023-07-11 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
| WO2015176161A1 (en) | 2014-05-23 | 2015-11-26 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| CN105394045B (zh) * | 2014-09-04 | 2020-02-14 | 中国科学院上海巴斯德研究所 | 一种肠道病毒的小分子化合物抑制剂及其应用 |
| US11266621B1 (en) | 2014-10-02 | 2022-03-08 | Exela Sterile Medicines Llc | Methocarbamol composition and related methods |
| WO2016059590A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of small molecule drugs and process for its preparation |
| TWI516520B (zh) | 2014-10-31 | 2016-01-11 | 財團法人工業技術研究院 | 波長轉換聚合物、其製法及包含其之波長轉換裝置 |
| US10039703B2 (en) | 2015-07-08 | 2018-08-07 | Triple Hair Inc. | Composition comprising resveratrol and melatonin for reducing hair loss and/or increasing hair regrowth |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US20170239250A1 (en) | 2016-02-19 | 2017-08-24 | Eagle Pharmaceuticals, Inc. | Pemetrexed formulations |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| CN105837556B (zh) * | 2016-04-11 | 2018-10-26 | 上海工程技术大学 | 一种来那度胺与烟酰胺共晶的制备方法 |
| EP3490552B1 (en) * | 2016-07-26 | 2022-11-23 | University of Southern California | Selective bromodomain inhibition of fungal bdf1 |
| WO2018042352A1 (en) * | 2016-08-31 | 2018-03-08 | Taro Pharmaceutical Industries | Fenoldopam topical formulations for treating skin disorders |
| MX2020012139A (es) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Composiciones y metodos para tratar rosacea y acne. |
| CN106841100A (zh) * | 2016-12-28 | 2017-06-13 | 北京医药集团有限责任公司 | 一种基于近红外光谱技术的小规格口服固体制剂中活性药物成分快速测定方法 |
| MA48047A (fr) * | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| WO2018191480A1 (en) * | 2017-04-12 | 2018-10-18 | Synergistic Therapeutics. Llc | Therapeutic neuropathic pain lotion |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| BR112021005104A2 (pt) * | 2018-10-16 | 2021-06-08 | US Nano Food & Drug INC | formulação de injeção intratumoral |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| WO2020092016A1 (en) * | 2018-10-31 | 2020-05-07 | Systamedic Inc. | Autophagy activators and inhibitors of ferroptosis for preventing acute renal failure and neurotoxcity induced by certain antibiotics |
| CN109627148B (zh) * | 2018-11-28 | 2021-09-03 | 中国农业科学院麻类研究所 | 一种大麻二酚的制备方法、制得的大麻二酚及其用途 |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| NZ781774A (en) | 2019-03-08 | 2023-03-31 | Taro Pharma Ind | Stable topical compositions of fenoldopam |
| MX2021011031A (es) | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
| WO2021108051A2 (en) * | 2019-10-25 | 2021-06-03 | Cmc Pharmaceuticals, Inc. | Atropine-scopolamine with enhanced stability |
| CA3160278A1 (en) * | 2019-12-04 | 2021-06-10 | Balasingam Radhakrishnan | Methods and compositions for treating edema refractory to oral diuretics |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| AU2021335500A1 (en) | 2020-09-04 | 2023-05-04 | Elanco Us Inc. | Palatable formulations |
| CN114181211B (zh) * | 2020-09-14 | 2024-05-28 | 鲁南制药集团股份有限公司 | 一种酮咯酸与苯甲酰胺共晶体及其制备方法 |
| CN112697945A (zh) * | 2020-12-18 | 2021-04-23 | 卓和药业集团有限公司 | 泊沙康唑肠溶片含量的分析方法 |
| CN117750948A (zh) * | 2021-03-23 | 2024-03-22 | 瑞科德治疗公司 | 用于靶向全身性递送至细胞的组合物和方法 |
| CN115212213A (zh) * | 2021-04-21 | 2022-10-21 | 广东东阳光药业有限公司 | 一种组合物及其制备方法 |
| CN113274379B (zh) * | 2021-05-25 | 2023-04-25 | 湖北工业大学 | Bephenium Hydroxynaphthoate在制备抗EV71药物的应用 |
| CN113768937B (zh) * | 2021-11-15 | 2022-04-08 | 恒翼生物医药科技(上海)有限公司 | 用于降低尿酸水平的化合物 |
| JP2025501169A (ja) * | 2021-12-27 | 2025-01-17 | エナラーレ セラピューティクス インコーポレイテッド | 呼吸刺激薬非経口製剤 |
| CN116492292A (zh) * | 2022-01-25 | 2023-07-28 | 上海维洱生物医药科技有限公司 | 一种安全、稳定的白消安注射液及其制备方法 |
| CN115721607B (zh) * | 2022-11-19 | 2023-07-21 | 华夏生生药业(北京)有限公司 | 一种乳酸左氧氟沙星注射液及其制备方法 |
| TW202434237A (zh) * | 2023-01-20 | 2024-09-01 | 香港商英矽智能科技知識產權有限公司 | Kif18a之抑制劑及其用途 |
| US20250032417A1 (en) | 2023-07-24 | 2025-01-30 | Hyloris Developments Sa | Lyophilized metolazone formulation for parenteral administration |
| WO2025054148A1 (en) * | 2023-09-07 | 2025-03-13 | Cfd Research Corporation | Co-administration of astemizole and an anticancer agent to treat cancer |
| CN118121554A (zh) * | 2024-03-14 | 2024-06-04 | 天津市保灵动物保健品有限公司 | 盐酸特比萘芬片剂 |
| CN119499175A (zh) * | 2024-11-23 | 2025-02-25 | 江西赣南海欣药业股份有限公司 | 一种注射用法莫替丁及其制备方法 |
| CN119757557B (zh) * | 2024-11-29 | 2026-01-30 | 上海市食品药品检验研究院 | 美白成分的检测方法 |
| CN119951294B (zh) * | 2025-02-14 | 2025-12-16 | 内蒙古优然牧业有限责任公司 | 一种用于牧场的生物除臭剂及其制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS475827Y1 (enExample) | 1970-04-02 | 1972-02-29 | ||
| JPS475827A (enExample) * | 1971-08-27 | 1972-03-29 | ||
| AU461715B2 (en) * | 1972-01-21 | 1975-05-19 | American Home Products Corporation | Parenteral benzodiazepine compositions |
| DE3316510A1 (de) | 1983-05-06 | 1984-11-08 | Bayer Ag | Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen |
| US4912124A (en) | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
| DE3702105A1 (de) | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
| JPH01242525A (ja) | 1988-03-25 | 1989-09-27 | Nippon Nohyaku Co Ltd | 抗真菌外用剤 |
| US5430057A (en) | 1993-09-30 | 1995-07-04 | Board Of Regents, The University Of Texas System | Parenteral busulfan for treatment of malignant disease |
| US5869474A (en) * | 1997-05-16 | 1999-02-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Low dosage treatment for cocaine craving and withdrawal |
| US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US7179475B1 (en) | 1998-12-04 | 2007-02-20 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| KR20070058028A (ko) | 1999-05-24 | 2007-06-07 | 소너스파머슈티칼즈인코포레이티드 | 난용성 약물용 에멀젼 부형제 |
| WO2001021154A2 (en) * | 1999-09-21 | 2001-03-29 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| GB2365770B (en) | 2000-08-18 | 2002-07-31 | Diomed Dev Ltd | Antifungal ketoconazole composition for topical use |
| US20030072807A1 (en) | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
| US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| JP2002322056A (ja) | 2001-04-27 | 2002-11-08 | Nippon Kayaku Co Ltd | トリアゾール誘導体の溶液製剤 |
| US6878693B2 (en) | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
| US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
| US6991800B2 (en) | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
| AU2003249510A1 (en) | 2002-08-12 | 2004-02-25 | Ranbaxy Laboratories Limited | A parenteral dosage form of selective cox-2 inhibitors |
| ZA200409537B (en) | 2003-01-31 | 2006-10-25 | Yamanouchi Pharma Co Ltd | Stable solid medicinal composition for oral administration |
| US9259390B2 (en) * | 2003-08-13 | 2016-02-16 | The University Of Houston System | Parenteral and oral formulations of benzimidazoles |
| GB0412866D0 (en) | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
| FR2872703B1 (fr) | 2004-07-07 | 2006-10-06 | Ethypharm Sa | Nanoparticules polymeriques composites |
| WO2006037106A2 (en) * | 2004-09-24 | 2006-04-06 | Rfe Pharma Llc | Carboxy-amido-triazoles for the localized treatment of ocular diseases |
| WO2006105399A1 (en) | 2005-03-31 | 2006-10-05 | Bristol-Myers Squibb Company | Methods for administering ixabepilone |
| WO2007002761A2 (en) | 2005-06-27 | 2007-01-04 | Barrier Therapeutics, Inc. | Micogel topical formulations |
| ITMI20051826A1 (it) | 2005-09-29 | 2007-03-30 | Novachem S A | Kit per la somministrazione parenterale di medicamenti |
| WO2007047253A2 (en) | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| EA015781B1 (ru) | 2005-10-21 | 2011-12-30 | Панацея Биотек Лимитед | Композиции для лечения рака |
| CA2639921C (en) | 2006-01-23 | 2014-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Microspheres comprising nanocapsules containing a lipophilic drug |
| US20070249546A1 (en) * | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| AU2007355106A1 (en) | 2006-11-29 | 2008-12-18 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
| JP5529539B2 (ja) | 2007-09-05 | 2014-06-25 | 株式会社ポーラファルマ | 医薬組成物 |
| HRP20191104T1 (hr) | 2007-09-25 | 2019-09-20 | Solubest Ltd. | Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu |
| US20090253712A1 (en) | 2008-04-03 | 2009-10-08 | Semmelweis Egyetem | Aqueous solvent system for solubilization of azole compounds |
| US20090286799A1 (en) | 2008-05-16 | 2009-11-19 | Zhi-Gang Jiang | Methods for the treatment of brain edema |
| CA2751412A1 (en) | 2009-02-05 | 2010-08-12 | Targeted Delivery Technologies Limited | Methods of reducing the proliferation and viability of microbial agents |
| US10130610B2 (en) | 2009-04-09 | 2018-11-20 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| CN103402543B (zh) * | 2010-12-16 | 2015-09-16 | 德克萨斯州立大学董事会 | 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法 |
| AU2012250050B2 (en) * | 2011-04-28 | 2017-04-06 | Platform Brightworks Two, Ltd. | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
-
2012
- 2012-04-20 AU AU2012250050A patent/AU2012250050B2/en active Active
- 2012-04-20 PL PL12719541T patent/PL2701684T3/pl unknown
- 2012-04-20 EP EP12719541.0A patent/EP2701684B1/en active Active
- 2012-04-20 WO PCT/US2012/034361 patent/WO2012148799A1/en not_active Ceased
- 2012-04-20 HU HUE17175794A patent/HUE051400T2/hu unknown
- 2012-04-20 CN CN201280032690.8A patent/CN103635179B/zh active Active
- 2012-04-20 CN CN201711217375.3A patent/CN107970209B/zh active Active
- 2012-04-20 HU HUE12719541A patent/HUE034480T2/en unknown
- 2012-04-20 ES ES17175794T patent/ES2822350T3/es active Active
- 2012-04-20 MX MX2013012579A patent/MX360638B/es active IP Right Grant
- 2012-04-20 ES ES12719541.0T patent/ES2640572T3/es active Active
- 2012-04-20 EP EP17175794.1A patent/EP3238709B1/en active Active
- 2012-04-20 DK DK17175794.1T patent/DK3238709T3/da active
- 2012-04-20 US US13/452,033 patent/US9364433B2/en active Active
- 2012-04-20 MX MX2018013788A patent/MX380805B/es unknown
- 2012-04-20 CA CA2834262A patent/CA2834262C/en active Active
- 2012-04-20 PL PL17175794T patent/PL3238709T3/pl unknown
- 2012-04-20 JP JP2014508441A patent/JP6080312B2/ja active Active
- 2012-04-20 DK DK12719541.0T patent/DK2701684T3/en active
- 2012-04-25 TW TW101114722A patent/TWI626059B/zh active
- 2012-04-26 AR ARP120101455A patent/AR086115A1/es not_active Application Discontinuation
-
2013
- 2013-10-24 IL IL229067A patent/IL229067B/en active IP Right Grant
-
2016
- 2016-05-13 US US15/154,919 patent/US9724345B2/en active Active
- 2016-10-24 JP JP2016208029A patent/JP2017014293A/ja active Pending
-
2017
- 2017-03-07 US US15/451,748 patent/US10028949B2/en active Active
-
2018
- 2018-06-21 US US16/014,908 patent/US10548890B2/en active Active
-
2020
- 2020-01-17 US US16/746,460 patent/US11045466B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013012579A (es) | Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilicos y metodos para prepararlos y usarlos. | |
| EA201492011A1 (ru) | Безводные фармацевтические составы для местного применения | |
| EP4360621A3 (en) | Formulations of bendamustine | |
| NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| WO2016134223A3 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| AR083016A1 (es) | Formulaciones liquidas para la agricultura con una mejor estabilidad | |
| IN2014MN02213A (enExample) | ||
| EA201270683A1 (ru) | Составы в виде лиофилизированного кека | |
| MX360420B (es) | Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma. | |
| NZ631345A (en) | Pharmaceutical compositions having improved storage stability | |
| MX381617B (es) | Conjugados de peptido-curcumina y formulaciones de los mismos. | |
| WO2014118808A3 (en) | Ticagrelor solid dispersion | |
| TW201613909A (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| PH12015502556A1 (en) | Modified release formulation | |
| MX2018004304A (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| MX388073B (es) | Composición farmacéutica, preparación y usos de la misma. | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| PH12015500681A1 (en) | Non-aqueous taxane nanodispersion formulations and methods of using the same | |
| MX2016003725A (es) | Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau. | |
| PH12016501117A1 (en) | Pharmaceutical compositions of carotenoid | |
| HK1223852A1 (zh) | 睪丸酮凝膠組合物及相關方法 | |
| WO2016005995A3 (en) | Glycol free stable liquid compositions of bendamustine | |
| GR1008234B (el) | Παρεντερικο σκευασμα ενος αντιμυκητιασικου παραγοντα τριαζολης και μεθοδος για την παρασκευη αυτου | |
| EA201500128A1 (ru) | Педиатрические жидкие композиции для перорального введения, содержащие непадутант | |
| WO2012029076A3 (en) | Stable pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |